Resources Archive - Page 2 of 48

Shortened Cardio-Metabolic Mouse Model of HFpEF

Current preclinical murine models of heart failure with preserved ejection fraction (HFpEF) require prolonged modeling periods, posing significant challenges for...

Efficacy of a TL1A Antibody in an Acute Colitis Mouse Model

Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is a chronic, immune-mediated disorder characterized by persistent inflammation...

Navigating the ADC Development Pathway

Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges....

GLP1R and GIPR Dual-Target Drugs in Humanized GIPR Mice

Multi-target drugs targeting GLP1R/GIPR/GCGR have demonstrated superior efficacy for weight loss and glycemic control compared to single-target GLP1R drugs. However,...

MSU-Induced Acute Gouty Arthritis Mouse Model

Gouty arthritis is a common, painful inflammatory condition characterized by the deposition of monosodium urate (MSU) crystals in joints. This...

Evaluations of Targeted Delivery Systems for RNA Therapeutics

RNA therapeutics can target specific mRNAs with high specificity, making them advantageous for treating genetic diseases caused by known mutations....

End-to-End CRDMO Platform for Oligonucleotide Drugs

Since the approval of the first siRNA drug in 2018, oligonucleotide therapeutics have rapidly emerged as a promising drug modality. ...

Integrated Platform Supporting ASO Drug Discovery

Antisense oligonucleotides (ASOs) are single-stranded, synthetic chains of DNA or RNA designed to bind to specific RNA sequences through complementary...

Evaluating Off-Targets of siRNA Drugs

siRNA holds great promise as a therapeutic modality due to its high specificity, developability, and sustained efficacy. However, its application...

Knowledge Library